LifeArc

What LifeArc does

LifeArc is an independent, self-funded not-for-profit medical research charity headquartered in London with research facilities in Edinburgh and Stevenage. Operating since 1992 (originally MRC Technology, rebranded in 2017), LifeArc focuses on translational science for diseases where commercial incentives are insufficient, principally rare diseases, motor neuron disease and rare dementias, chronic and rare respiratory disease, childhood cancer, and global health threats including antimicrobial resistance.

The organisation runs five core scientific platforms: antibody humanisation and discovery (using its proprietary Kymouse transgenic platform and single B-cell technologies, with a 30-year track record including contributions to Keytruda), small molecule drug discovery including PROTACs and E3 ligase-based targeted protein degradation, ISO 13485-certified diagnostics development, clinical development support, and data science spanning cheminformatics, bioinformatics, and AI/ML. It also operates iPSC disease modelling for neurodegeneration and an early-stage venture investment arm (LifeArc Ventures).

LifeArc is funded primarily through returns on a £1.255bn investment portfolio (December 2024) following its 2019 royalty monetisation of Keytruda (pembrolizumab). Additional income comes from service agreements, royalties, milestones, and venture returns. The charity operates through partnerships with academia, NHS hospitals, other charities, regulators (MHRA), and industry; it does not sell products commercially and instead deploys funding, scientific expertise, and venture capital to de-risk translational programmes that it then hands off to commercial partners, spin-out companies such as RQ Bio, or new initiatives such as the integrated Rare Therapies Launch Pad for individualised medicines.

Name

LifeArc

Legal name

LifeArc

Website

https://www.lifearc.org/

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

251–500 employees

Short description

LifeArc is a self-funded UK medical research charity that translates science into treatments for rare diseases, motor neuron disease, childhood cancer, respiratory disease, and global health, offering antibody humanisation, drug discovery, diagnostics, clinical, and data science services backed by a £1.255bn investment portfolio.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Investment Portfolio Returns: LifeArc's fundamental income source comes from their investment portfolio which stood at £1.255 billion as of December 2024. They invest in diverse asset classes including global equities, fixed-income investments, private markets, infrastructure, real estate and hedge funds, seeking to outpace UK annual wage inflation by 3.5% per year over the long term. Returns fund translational activity.
2. Royalty and Milestone Payments: When collaborating on projects, LifeArc receives portions of royalty interest. In 2019, they monetized a portion of their royalty interests in the cancer medicine Keytruda (pembrolizumab). They also receive income from service agreements, royalties, and milestones.
3. LifeArc Ventures Investment Returns: LifeArc Ventures invests in early-stage science-led companies, providing seed and series A investments with scientific support through expert scientists and labs. Financial returns from investments are returned to LifeArc to further its charitable goals.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels10 records

Core offering

LifeArc is a self-funded medical research charity that provides translational science services to academic, biotech, pharmaceutical, and charity partners. Its core offerings include antibody humanization and discovery using the Kymouse platform, small molecule drug discovery, diagnostics development in an ISO 13485-certified environment, clinical development support, and data science/AI capabilities. It also runs LifeArc Ventures for seed and Series A investment in early-stage life sciences companies, alongside co-funding programs (PACE, C-Further, Bio-Hermes-002, Translational Centres for Rare Disease) targeting MND, rare dementias, respiratory disease, childhood cancer, rare disease, and global health.

Product overview

LifeArc is a not-for-profit medical research organisation offering a comprehensive portfolio of translational science services across five focus areas: Motor Neuron Disease & Rare Dementias, Chronic & Rare Respiratory Disease, Rare Disease, Childhood Cancer, and Global Health. The core service offerings include Antibody Development Services (humanisation and discovery using Kymouse platform), Clinical Development Support, Data Science Services, Diagnostics Development (ISO 13485-certified), and Small Molecule Drug Discovery. LifeArc Ventures provides early-stage investment and scientific support to biotech companies. The organisation also operates major partnership-enabled initiatives including the C-Further Consortium for paediatric oncology, PACE for antimicrobial resistance, Bio-Hermes-002 for Alzheimer's diagnostics, and the LifeArc Translational Centres for Rare Disease. Additional offerings include the Rare Therapies Launch Pad for individualised medicines and various patient engagement programmes such as the MND Insights Group.

Differentiator

Problem solved

Functional benefit

Brands

• LifeArc Ventures: Early-stage venture investment arm that invests in science-led companies in therapeutics, HealthTech and medical devices.
• MRC Technology (former name)

Products and services

• Antibody Development Services Advanced antibody humanisation and discovery services for academic, biotech, and pharma partners, leveraging the proprietary Kymouse transgenic platform and single B-cell technologies to generate fully human therapeutic monoclonal antibodies.
• Clinical Development Support Bespoke clinical development strategies and planning support for partners, covering clinical affairs, trial design and operations, regulatory compliance, and patient and healthcare professional engagement.
• Data Science Services Data science team providing cheminformatics, computational chemistry, bioinformatics, clinical and health data analysis, data engineering, and AI/ML capabilities for drug discovery and clinical pathways, including gold-standard iPSC models for neurodegeneration.
• Diagnostics Development Services Comprehensive diagnostic development support from assay design through clinical validation, operating in an ISO 13485-certified development environment with regulatory mapping and commercial partner facilitation.
• Small Molecule Drug Discovery State-of-the-art small molecule drug discovery service in Stevenage providing medicinal chemistry, assay development, structural biology, in silico screening, and targeted protein degradation capabilities including PROTACs and E3 ligases.
• LifeArc Ventures Early-stage life science investment arm providing seed and Series A funding to science-led companies, with scientific support through LifeArc's expert scientists and labs in Stevenage and Edinburgh.

Quantifiable outcome

• 5 licensed medicines from humanized antibodies including Keytruda
• +4 more outcomes

Named customers8 records

Segments8 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

28 partnerships are on record, tiered core and major.

• RQ BiocoreStrategic or Co-development Partner · 24 June 2026LifeArc co-founded and backed RQ Bio, a UK biotech company developing long-acting antibody RQB01 for influenza prevention. LifeArc provided early investment, strategic support, initial start-up facilities, and drug discovery expertise including CMC de-risking and antibody engineering. RQ Bio secured $115 million (£85.5 million) Series A financing.
• Rare Disease ConsortiumcoreStrategic or Co-development Partner · 28 May 2026MHRA partnership with Rare Disease Consortium comprising patients, academics, industry and healthcare partners to develop new regulatory framework for rare disease therapies.
• Elpida TherapeuticscoreStrategic or Co-development Partner · 27 May 2026LifeArc partnered with Elpida Therapeutics to support development of three gene therapy programs targeting ultra-rare neurodegenerative conditions in children, including SPG50, CLN7 Batten disease, and CMT4J. LifeArc provides clinical, translational, and regulatory expertise alongside financial support, focusing on UK and Europe, aiming to create a blueprint for developing rare disease therapies.
• Bill & Melinda Gates FoundationcoreStrategic or Co-development Partner · 16 April 2026LifeArc and Gates Foundation awarded funding to seven new projects focused on reducing costs of manufacturing monoclonal antibodies from over $50-100 per gram to below $10, enhancing accessibility in resource-limited settings.
• ALS Therapy Development Institute (ALS TDI)coreStrategic or Co-development Partner · 1 April 2026LifeArc, ALS TDI, and Axol Bioscience launched the PRISM initiative to develop diverse patient-derived stem cell models for ALS/MND research, aiming to improve understanding of disease mechanisms and therapeutic development.
• C-Further ConsortiumcoreStrategic or Co-development Partner · 10 March 2026International consortium dedicated to childhood cancer therapeutics with $40 million (£30 million) initial budget. Core partners include Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity. First programs include CF-012 for Ewing sarcoma and CF-033 for multiple children's cancers.
• Cancer Research HorizonscoreStrategic or Co-development Partner · 10 March 2026Core partner in C-Further Consortium advancing innovative cancer therapies for children and young people.
• Great Ormond Street Hospital CharitycoreStrategic or Co-development Partner · 10 March 2026Core partner in C-Further Consortium advancing innovative cancer therapies for children with initial $40 million budget.
• Global Alzheimer's Platform FoundationcoreStrategic or Co-development Partner · 21 January 2026LifeArc and GAP co-lead the Bio-Hermes-002 study testing a finger-prick blood test for Alzheimer's diagnosis. The international clinical trial involves 1,000 volunteers aged over 60 across UK, US and Canada, analyzing biomarkers including phosphorylated tau 217, GFAP, and Neurofilament light polypeptide.
• UK Dementia Research InstitutecoreStrategic or Co-development Partner · 21 January 2026Partner with LifeArc and Global Alzheimer's Platform Foundation on Bio-Hermes-002 study for Alzheimer's diagnostic test.
• Genomics EnglandcoreStrategic or Co-development Partner · 1 January 2026Founding partner of Rare Therapies Launch Pad, a UK-led multi-stakeholder initiative to accelerate development and delivery of individualised medicines for rare diseases.
• Association of the British Pharmaceutical IndustrycoreStrategic or Co-development Partner · 1 January 2026Founding partner of Rare Therapies Launch Pad alongside Genomics England, universities, hospitals and patient foundations.
• Mila's Miracle FoundationcoreStrategic or Co-development Partner · 1 January 2026Founding partner of Rare Therapies Launch Pad, focused on advancing individualised medicines for rare diseases.
• NHS Blood and TransplantcoreStrategic or Co-development Partner · 1 January 2026Manufacturing support for CTLA-4 insufficiency gene therapy through NHSBT's Clinical Biotechnology Centre, part of Innovation Hubs for Gene Therapies network.
• University College London (UCL)coreStrategic or Co-development Partner · 1 January 2026Developing first-of-its-kind gene therapy for CTLA-4 insufficiency with scientists at UCL, with clinical trial planned for 2028.
• Oxford PharmaGenesismajorStrategic or Co-development Partner · 1 January 2024LifeArc and Oxford PharmaGenesis established the MND Insights Group in 2024 to integrate lived experience of MND into research funding and design decisions, convening patients and bereaved caregivers over 1.5 years.
• Motor Neuron Disease AssociationcoreStrategic or Co-development Partner · 24 January 2023LifeArc, MND Association, and My Name'5 Doddie Foundation awarded £1 million to researchers at UCL to develop gene and cell therapies for motor neuron disease, aiming to slow disease progression and restore muscle function.
• My Name'5 Doddie FoundationcoreStrategic or Co-development Partner · 24 January 2023Joint £1 million grant with LifeArc and MND Association to UCL researchers for MND gene and cell therapy development.
• Dementia ConsortiummajorStrategic or Co-development Partner · 1 January 2013LifeArc joined drug discovery collaboration with Alzheimer's Research UK in 2013 to advance dementia research.
• UK Dementia Research Institute (UK DRI)coreStrategic or Co-development Partner£30 million partnership with UK DRI to accelerate development of new diagnostic tests, treatments, and devices for people with dementia.
• Our Future HealthcoreStrategic or Co-development PartnerPartnership to use health data expertise to uncover insights into disease progression, stratify patient groups and accelerate clinical trials.
• Great Ormond Street Hospital (GOSH)coreStrategic or Co-development PartnerCollaboration on KidsRare initiative to safely connect paediatric rare disease health data - a first-of-its-kind UK health data initiative.
• Cystic Fibrosis TrustcoreStrategic or Co-development Partner£15 million partnership over 5 years to establish collaborative network of 4 research hubs accelerating development of new diagnostics and therapeutics for lung infections in cystic fibrosis.
• Innovate UKcoreStrategic or Co-development PartnerPACE (Pathways to Antimicrobial Clinical Efficacy) - £30 million collaborative initiative with Innovate UK and Medicines Discovery Catapult to tackle antimicrobial resistance.
• Medicines Discovery CatapultcoreStrategic or Co-development PartnerPACE initiative partner driving new developments to tackle antimicrobial resistance.
• Liverpool School of Tropical MedicinecoreStrategic or Co-development PartnerPartnership with LSTM to launch £2.7 million Translational Development Fund through the Infection Innovation Consortium (iiCON).
• Francis Crick InstitutecoreStrategic or Co-development PartnerPartnership with Crick Africa Network providing £7.5 million towards community science programmes in Africa.
• KisoJi BiotechnologymajorStrategic or Co-development PartnerLifeArc humanized the first unconjugated antibody against TROP-2 for KisoJi Biotechnology, advancing it into clinical development.

Scale indicators16 records

Recent moves9 records

Expansion highlights8 records

Broad incumbents

• Wellcome Trust: Largest UK biomedical charity with multi-billion pound endowment funding translational and basic research globally. Comparable self-funded charitable model, broader scope but similar patient-impact mission and capability to deploy substantial capital into translational partnerships.
• Howard Hughes Medical Institute (HHMI): US biomedical research organization with $20B+ endowment funding investigator-initiated research and translational science. Closest international parallel to LifeArc's model of endowment-funded scientific activity focused on patient impact.
• Medical Research Council (MRC): UK government-funded research council that LifeArc originated from. Comparable mission of funding translational biomedical research, though MRC operates as a grant-making body rather than conducting science directly.

Regional players

• Innovate UK: UK government innovation agency co-funding LifeArc's PACE initiative. Comparable funder of translational and commercial R&D in the UK life sciences sector with overlapping target beneficiaries.

Direct peers

• Cystic Fibrosis Foundation: US patient-driven charity funding CF therapeutics and translational research, with venture-style royalty monetization (Vertex partnership). Active LifeArc partner in CF translational hubs (£15M over 5 years) and structurally similar charitable translational model.
• Medicines Discovery Catapult: UK non-profit supporting drug discovery innovation with public funding. Direct peer and consortium partner (PACE) with overlapping capabilities in translational support services and shared focus on antimicrobial resistance.
• Francis Crick Institute: UK biomedical discovery institute where LifeArc hosts a partnership team. Comparable mission of advancing fundamental research toward patient benefit and operates in close geographic/scientific proximity in London's translational ecosystem.
• Cancer Research Horizons: The commercial arm of Cancer Research UK, performing translational drug discovery and development. Direct peer and consortium partner (C-Further) given shared model of charity-funded translational science, antibody/diagnostic development services, and venture-style investments in oncology.
• Harrington Discovery Institute: US-based non-profit accelerating drug discovery from academic labs via funding, scientific support, and venture creation. Closest US analogue to LifeArc's translational charity model, particularly for rare diseases.

Emerging players

• Bill & Melinda Gates Foundation: Massive philanthropic foundation funding global health innovation including LifeArc's mAb manufacturing cost-reduction projects. Comparable mission in addressing translational gaps, particularly for infectious diseases in resource-limited settings, and active co-funder.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/lifearc1
• YouTubeyoutube.com/user/MRCTechnology
• LinkedInlinkedin.com/company/278071

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles23 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments18 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeArc